ClinicalTrials.govpublic full text
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
primary sjogren's syndrome, lymphoma, car-nk, dose limiting toxicity, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 865027
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.